“The meaningful changes seen in a short trial are very encouraging,” said Dr. CJ Barnum, Vice President of CNS Drug Development at INmune Bio. “We are honored that Dr. Sharon Cohen will present our ...

A live audio webcast of the Company’s presentation will be available by visiting Castle Biosciences’ website at ir.castlebiosciences.com/events-presentations/. A replay of the webcast will be ...

BriaPro is a pre-clinical stage immunotherapy company developing binding agents and proteins with the intention to boost the ability of the body’s own cancer-fighting cells to destroy cancerous tumors ...

Sovateltide, a potential first-in-class, highly selective endothelin-B (ETB) receptor agonist, has previously demonstrated significant improvement in stroke patients compared to standard of care in a ...

Microbix Biosystems Inc. ( TSX: MBX, OTCQX: MBXBF, Microbix® ), a life sciences innovator, manufacturer, and exporter, announces the commercial launch of QUANTDx™, a new product line of ...

Molecular breast imaging (“ MBI ”) is an emerging modality that uses gamma radiation and injectable radioactive tracers. It is typically reserved for investigational diagnostic imaging and delivers a ...

The Company continued further restructuring activities during 2025 including severance, employee-related and facility exit costs. Cost of goods sold includes the benefit received from the sale of ...

Mike Doustdar has been appointed as the result of a comprehensive process that included external and internal candidates. The Novo Nordisk Foundation fully endorses Novo Nordisk Board’s decision to ...

For those pushing beyond average gains, the CrazyBulk Growth Hormone Stack is engineered for elite-level performance and ...

Kiniksa is recruiting patients in the dose-focusing portion of the Phase 2/3 clinical trial of KPL-387 in recurrent pericarditis. The company expects data from this portion of the trial in the second ...

In April 2025, Radiopharm dosed the first patient in the U.S. Phase 2b imaging study of 18F-RAD101. The multicenter, open-label, single arm Phase 2b clinical trial is evaluating the diagnostic ...

The lowered sales outlook for 2025 is driven by lower growth expectations for the second half of 2025. This is related to lower growth expectations for Wegovy ® in the US obesity market, lower growth ...